A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMSD Italia S.r.l.
About this trial
This is a non-interventional, retrospective observational study to improve knowledge regarding the diagnosis and treatments of patients who have/had non-small cell lung cancer (NSCLC), either early stage (stage I-II).
Eligibility criteria
Qualifiers
Patients with stage I-III NSCLC who have received curative surgery or radiotherapy between January 2018 and June 2019 with available follow-up through January 2021
Adult patients (aged ≥ 18 years) at the moment of diagnosis
Patients (or their legally acceptable representatives) must have signed and dated the Informed Consent form; privacy Form (ICF). In case of deceased or untraceable patient the investigator before collecting data shall demonstrate and report all necessary measures adopted to contact the patient.
Disqualifiers
Patients without availability of medical charts or information required
Enrollment in studies imposing a specific patient's management strategy which does not correspond to the site's normal clinical practice.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
25IRCCS Casa di sollievo dalla sofferenza San Giovanni RotondoFG, Italy
ASST degli Spedali Civili di Brescia Brescia Italy
Gemelli Molise Campobasso Italy
Humanitas Istituto Clinico Catanese Catania Italy
Sponsors and collaborators
MSD Italia S.r.l.
Lead sponsor
YGHEA, CRO Division of Ecol Studio spa
Collaborator
Source ClinicalTrials.gov